# Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment

> **NCT05328167** · PHASE2 · COMPLETED · sponsor: **Thomas Jefferson University** · enrollment: 16 (actual)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **DRUG:** Perflutren Protein-Type A Microspheres
- **PROCEDURE:** Contrast-Enhanced Ultrasound

## Key facts

- **NCT ID:** NCT05328167
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-14
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-08-31
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05328167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05328167, "Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05328167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*